Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

31.53
-0.4500-1.41%
Pre-market: 31.720.1900+0.60%04:00 EDT
Volume:1.85M
Turnover:58.54M
Market Cap:3.68B
PE:-6.76
High:32.43
Open:31.70
Low:31.39
Close:31.98
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:1.00
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:9.01
PE(LYR):-9.88

Loading ...

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Yesterday

GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market

Options & Short Sell
·
Yesterday

Viking Therapeutics to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Der Aktionaer editor speculates on timing of Viking Therapeutics data

TIPRANKS
·
Aug 25

Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In

Simply Wall St.
·
Aug 20

Viking Therapeutics Director Dorothy Elizabeth Kelly-Gemmell Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Viking Therapeutics Posts Corporate Presentation Outlining Obesity Drug Pipeline Led by Vk2735 Phase 3 Program

Reuters
·
Aug 06

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live
·
Aug 04

Oppenheimer says VK2735’s options create compelling reason to own Viking

TIPRANKS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), AbbVie (ABBV) and Cencora (COR)

TIPRANKS
·
Aug 01

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

MT Newswires Live
·
Jul 31

Viking Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 31

Viking Therapeutics (VKTX) Receives a Buy from Jefferies

TIPRANKS
·
Jul 30

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Viking Therapeutics Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 30

Viking Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30

Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year

TIPRANKS
·
Jul 30